Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma

More about Open Access at the Crick

Abstract

Cancer mutations generate novel (neo-)peptides recognised by T cells, but the determinants of recognition are not well characterised. The difference in predicted class I major histocompatibility complex (MHC-I) binding affinity between wild-type and corresponding mutant peptides (differential agretopicity index; DAI) may reflect clinically relevant cancer peptide immunogenicity. Our aim was to explore the relationship between DAI, measures of immune infiltration and patient outcomes in advanced cancer.

Journal details

Volume 29
Issue number 1
Pages 271-279
Available online
Publication date